Latest News

Barcelona, Spain (UroToday.com) Neoadjuvant platinum-based chemotherapy is the standard of care for high-risk resectable urothelial carcinoma (Stage III; cT3-T4aN0M0 or cT1N+M0). Though response rates are quite high, and pathologic complete responses occur in approximately 25% of patients, these tumors commonly recur such that the marginal overall survival benefit from neoadjuvant chemotherapy is only 5%. As 30-40% […]

Barcelona, Spain (UroToday.com) Though significant progress has been made in elucidating molecular alterations in metastatic castration-resistant prostate cancer (mCRPC), no biomarker-selected targeted therapeutic options have existed in this disease until today. Dr. Hussain and colleagues presented analysis of the PROfound study, a randomized phase III biomarker driven trial in mCRPC of olaparib in patients harboring […]

Barcelona, Spain (UroToday.com) Dr. Joaquim Bellmunt provided the invited discussant for:  Dr. Bellmunt highlighted that NABUCCO was a single-arm phase IB trial testing the feasibility of pre-operative ipilimumab + nivolumab in stage III urothelial carcinoma patients who were either cisplatin ineligible or refused chemotherapy. Feasibility was the primary endpoint, which was met in that 96% […]

Barcelona, Spain (UroToday.com) ADAPTeR (NCT02446860) is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). The primary endpoint of this study was safety with secondary endpoints of objective response rate (ORR), progression-free survival (PFS), and overall survival […]

Barcelona, Spain (UroToday.com) In this special symposium, Dr. Siefker-Radke discussed the current status and future directions of combination chemo-immunotherapy in advanced urothelial carcinoma. While the full results of IMvigor130 were unavailable at the time of this presentation, Dr. Siefker-Radke focused on the clinical and biologic rationale for combination approaches. Given the unmet clinical need for […]

Barcelona, Spain (UroToday.com) Dr. Joaquim Bellmunt provided an overview of the current state of immune checkpoint inhibition in advanced urothelial cancer, emphasizing the clinical uses based on available data as well as future directions for clinical development of immunotherapy and novel immune-oncology combinations. He began by summarizing the results from the pivotal trial of the […]

Barcelona, Spain (UroToday.com) The role of upfront cytoreductive nephrectomy (uCN) in patients with metastatic renal cell carcinoma (mRCC) is currently under debate as systemic therapy alone (sunitinib) was recently demonstrated to be noninferior.1 Since that time, combination immunotherapy and immunotherapy plus VEGF tyrosine kinase inhibitor (TKI) combination regimens have demonstrated efficacy in patients with previously-untreated […]